Basic information |
Metabolite name | LysoPC(16:0) |
N/A | |
C04230 | |
N/A | |
Synonyms | LPC(16:0); |
No. of studies | 38 |
Relationship between LysoPC(16:0) and depression (count: 38) |
Study | Study Type | Comparison groups | Tissue | Organism | Up/Down regulated |
Study M007 | Type1 | CRS group vs. control group | Plasma | Wistar rat | Up |
Study M029 | Type1 | CUMS group vs. control group | Brain | Sprague-Dawley rat | Up |
Study M029 | Type2 | CUMS + BHD group vs. CUMS group | Brain | Sprague-Dawley rat | Down |
Study M048 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Down |
Study M048 | Type1 | CVS group vs. control group | Serum | Wistar rat | Down |
Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Serum | Wistar rat | Up |
Study M048 | Type2 | CVS + CSGS group vs. CVS group | Hippocampus | Wistar rat | Up |
Study M048 | Type2 | CVS + CSGS group vs. CVS group | Serum | Wistar rat | Up |
Study M048 | Type2 | CVS + fluoxetine group vs. CVS group | Hippocampus | Wistar rat | Up |
Study M061 | Type1 | depressed group vs. control group | Plasma | Human | Up |
Study M072 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
Study M072 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Up |
Study M076 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
Study M076 | Type2 | CUMS + fluoxetine group vs. CUMS group | Hippocampus | Sprague-Dawley rat | Down |
Study M084 | Type1 | melancholic depressed group vs. control group | Plasma | Human | Up |
Study M095 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
Study M096 | Type1 | CUMS group vs. control group | Hippocampus | Wistar rat | Up |
Study M096 | Type2 | CUMS + paroxetine group vs. CUMS group | Hippocampus | Wistar rat | Down |
Study M1072 | Type1 | CUMS group vs. control group | Faece | Cynomolgus monkey | Down |
Study M1086 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
Study M1117 | Type1 | MDD group vs. control group, Chinese cohort | Plasma | Human | Up |
Study M1117 | Type1 | MDD group vs. control group, Russian cohort | Plasma | Human | Down |
Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Down |
Study M122 | Type3 | paroxetine group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
Study M122 | Type3 | maprotiline group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
Study M123 | Type3 | rTMS group vs. control group | Striatum | Wistar rat | Down |
Study M124 | Type3 | maprotiline group vs. control group | Prefrontal cortex | BALB/c mouse | Up |
Study M125 | Type1 | depressed group vs. control group | Plasma | Human | Up |
Study M457 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
Study M532 | Type1 | MDD group vs. control group | Plasma | Human | Up |
Study M540 | Type1 | CUMS group vs. control group | Hippocampus | Sprague-Dawley rat | Up |
Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
Study M582 | Type2 | CUMS + fluoxetine group vs. CUMS group | Serum | C57BL/6N mouse | Down |
Study M582 | Type2 | CUMS + fluoxetine group vs. CUMS group | Faece | C57BL/6N mouse | Down |
Study M582 | Type3 | control + fluoxetine group vs. control group | Faece | C57BL/6N mouse | Down |
Study M582 | Type3 | control + fluoxetine group vs. control group | Hippocampus | C57BL/6N mouse | Up |
Study M613 | Type1 | CSDS susceptible group vs. control group | Nucleus accumbens | C57BL/6 J mouse | Down |
Study M651 | Type1 | LPS group vs. control group | Plasma | C57BL/6 mouse | Up |
Study M651 | Type2 | LPS + fish oil group vs. LPS group | Plasma | C57BL/6 mouse | Down |
Study M676 | Type1 | CVS group vs. control group | Hippocampus | Wistar rat | Up |
Study M676 | Type2 | CVS + Chaihu-Shu-Gan-San group vs. CVS group | Hippocampus | Wistar rat | Down |
Study M681 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
Study M681 | Type2 | CUMS + Chaihu Shu Gan San group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
Study M690 | Type2 | CUMS + high dose of Zhi-zi-chi decoction group vs. CUMS group | Serum | Balb/c mouse | Up |
Study M744 | Type1 | CUS transplant group vs. control transplant group | Hippocampus | Sprague-Dawley rat | Down |
Study M774 | Type1 | MDD group vs. control group | Serum | Human | Down |
Study M789 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
Study M789 | Type2 | CUMS + fluoxetine group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
Study M789 | Type2 | CUMS + liquiritin group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
Study M815 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
Study M815 | Type2 | CUMS + high dose of Radix Bupleuri–Radix Paeoniae Alba group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
Study M815 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
Study M826 | Type1 | CVS group vs. control group | Colorectum | Wistar rat | Up |
Study M835 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Down |
Study M835 | Type1 | CRS group vs. control group | Faece | C57BL/6 mouse | Up |
Study M880 | Type1 | depression group vs. control group | Plasma | Cynomolgus monkey | Down |
Study M890 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
Study M907 | Type1 | MDD group vs. control group | Plasma | Human | Down |
Study M948 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
Study M955 | Type1 | CUMS group vs. control group | Hippocampus | C57BL/6J mouse | Down |
Study M955 | Type2 | CUMS + deoiled sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |
Study M955 | Type2 | CUMS + tryptophan-enriched whey protein-based group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |
Study M955 | Type2 | CUMS + deoiled and dechlorogenic acid-enriched sunflower seeds group vs. CUMS group | Hippocampus | C57BL/6J mouse | Up |